CREUTZFELDT JAKOB DISEASE: Creutzfeldt-Jakob disease in a man with COVID-19: SARS-CoV-2-accelerated neurodegeneration?

Creutzfeldt-Jakob disease in a man with COVID-19: SARS-CoV-2-accelerated neurodegeneration?

Author links open overlay panelMichael J.YoungMeabhO'HareMarceloMatielloJeremy D.Schmahmann

https://doi.org/10.1016/j.bbi.2020.07.007

Abstract

We describe a man whose first manifestations of Creutzfeldt-Jakob disease occurred in tandem with symptomatic onset of coronavirus disease 2019 (COVID-19). Drawing from recent data on prion disease pathogenesis and immune responses to SARS-CoV-2, we hypothesize that the cascade of systemic inflammatory mediators in response to the virus accelerated the pathogenesis of our patient’s prion disease. This hypothesis introduces the potential relationship between immune responses to the novel coronavirus and the hastening of preclinical or manifest neurodegenerative disorders. The global prevalence of both COVID-19 and neurodegenerative disorders adds urgency to the study of this potential relationship.

snip...

1. Discussion

Neurological manifestations of COVID-19 include headache, delirium, anosmia, increased stroke risk, dizziness, and encephalitis (Wu et al., 2020). This first report of CJD in a patient with COVID-19 may reflect pure coincidence, given the high, likely underestimated, prevalence of clinically manifest and asymptomatic COVID-19, and the annual incidence of CJD of approximately 1 per million. However, this case raises the specter of a clinically meaningful interaction in which infection with SARS-CoV-2 precipitates or accelerates neurodegenerative diseases.

Animal and human studies of neurodegenerative disease and brain injury show that release of pro-inflammatory cytokines – IL-1, IL-6, IL-12, and TNFα by activated microglia or reactive A1-astrocytes in the course of a systemic immune response promote neuroinflammation and may accelerate disease progression in Alzheimer disease (Holmes et al., 2009), Parkinson disease (Tan et al., 2020), multiple system atrophy (Hoffmann et al., 2019), frontotemporal dementia (Bright et al., 2019), progressive supranuclear palsy, primary progressive aphasia, and stroke (Khandelwal and Herman, 2011). Fast neurodegeneration is associated with elevation of plasma IL-13, TNF- α and G-CSF in rapidly progressive AD (Stoeck et al., 2014).

CJD is caused by the accumulation of abnormally folded, protease-resistant isoforms of host cellular sialoglycoproteins (i.e., prion proteins). Accumulation predominantly of prion protein scrapie, PrPSc, leads to vacuolation and spongiform neuropathologic changes coinciding with rapid neurodegeneration and activation of astrocytes and microglia in affected regions. Animal studies demonstrate accelerated transition from pre-clinical to clinical stages of prion disease in settings of co-infection. Mice co-infected with T. muris after direct CNS PrPSc injections developed a polarized immune response with increased CD8+ T cell recruitment, and elevated levels of pro-inflammatory cytokines including IFN-γ, and enhanced activation of A1 reactive astrocytes that significantly shortened time to development of clinical signs (Donaldson et al., 2020).

Depending on local milieu, astrocytes may be induced to assume one of two distinct reactive forms: a neurotoxic A1 phenotype and a neuroprotective A2 phenotype. A1 astrocytes potentiate death of neighboring neurons and oligodendrogliocytes (Liddelow et al., 2017). Il-1, TNF and C1q are collectively necessary and sufficient for A1 astrocyte activation (Liddelow et al., 2017). In prion disease, A1 reactive astrocytes are thought to be neurotoxic by mediating neuronal damage of adjacent neuronal processes and serving as foci for PrPSc propagation (Makarava et al., 2020). Pre-clinical CJD is marked by retention of region-specific homeostatic identities of glia, including astrocytes. During the transition to clinical CJD these region-specific signatures are lost and replaced by a neuroinflammatory transcriptome signature that affects astrocyte sub-populations in a region-dependent manner (Makarava et al., 2020).

The simultaneous clinical presentations of COVID-19 and CJD in this patient led us to hypothesize that the cascade of systemic inflammatory mediators that characterize COVID-19 may have accelerated the prion disease pathogenesis and neurodegeneration by facilitating loss of region-specific homeostatic identities of astrocytes and fostering a neuroinflammatory transcriptional signature. The molecular mechanism remains to be determined, but there is empirical support for our hypothesis in that there is inflammasome activation and increased secretion of Il-1 (Cavalli et al., 2020), TNF and complement cascade in COVID-19 (Merad and Martin, 2020), and the fact that Il-1, TNF and C1q are necessary and sufficient for activation of A1 astrocytes (Liddelow et al., 2017) which affect prion propagation.

Lateralized presentation of CJD has been reported previously. Notably, lateralized modulation of immune function (Neveu, 2002) and inter-hemispheric asymmetry in basal levels of cytokines and distribution of microglia are documented (Fu et al., 2003), perhaps predisposing to asymmetric prion disease propagation and neurodegeneration, and compounded by systemic inflammatory responses.

Neurological dysfunction in COVID-19 is likely caused by immune responses systemically and within the nervous system (Farhadian et al., 2020). Our hypothesis that inflammatory responses to SARS-Cov-2 precipitate or exacerbate neurodegenerative disease is urgent because COVID-19 portends disproportionately worse outcomes in the elderly who are already at risk of neurodegenerative disease.

see full text ;

https://www.sciencedirect.com/science/article/pii/S0889159120315221

SUNDAY, OCTOBER 21, 2018

Surveillance for variant CJD: should more children with neurodegenerative diseases have autopsies? Singeltary Review

http://creutzfeldt-jakob-disease.blogspot.com/2018/10/surveillance-for-variant-cjd-should.html

MONDAY, OCTOBER 05, 2020

USA, UK, JAPAN, CJD TSE PRION STATISTICS UPDATE OCTOBER 2020

https://creutzfeldt-jakob-disease.blogspot.com/2020/10/usa-uk-japan-cjd-tse-prion-statistics.html

http://creutzfeldt-jakob-disease.blogspot.com/

FRIDAY, OCTOBER 2, 2020

H.R.925 America's Conservation Enhancement Act 116th Congress 2019-2020 SEC 104 CHRONIC WASTING DISEASE TASK FORCE

https://animalhealthreportpriontse.blogspot.com/2020/10/hr925-americas-conservation-enhancement.html